Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 11/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15451916 | 0.82 | SMYD3 (0.45) | SMYD3 | |
| SCHEMBL31234425 | 0.79 | — | — | |
| SCHEMBL17831922 | 0.78 | SMYD3 (0.47) | SMYD3DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL13406229 | 0.71 | SMYD3 (0.51) | SMYD3 | |
| SCHEMBL20066505 | 0.71 | SMYD3 (0.41) | SMYD3NPC1TSHRRAB9A | |
| SCHEMBL12310294 | 0.71 | SMYD3 (0.41) | SMYD3DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3165224 | 0.70 | SMYD3 (0.52) | SMYD3 | |
| SCHEMBL19895092 | 0.69 | S1PR3 (0.35) | RETSMYD3STAT1NPC1TSHR | |
| SCHEMBL1556567 | 0.69 | KMO (0.36) | — | |
| SCHEMBL12766413 | 0.69 | SMYD3 (0.38) | SMYD3STAT1NPC1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751873-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751873-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-9115101-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
| EP-1615699-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092124-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | RET 900/4885SMYD3 1814/4885DRD2 2148/4885 |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | RET 900/4885SMYD3 1814/4885DRD2 2148/4885 |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | RET 1166/4885SMYD3 1692/4885DRD2 2358/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | RET 884/4885SMYD3 1842/4885DRD2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.